Glucagon and Food Bolus: Key Drivers in Peptide Product Composition and Market Trends
Abstract: Glucagon and food bolus critically influence peptide product composition, driving market trends toward enhanced bioavailability and stability. Current industry data reveals a 12.3% CAGR in therapeutic peptides, with glucagon-like formulations dominating diabetes and obesity segments. Brand comparisons highlight trade-offs: Novo Nordisk’s liraglutide offers superior half-life (13h) versus generic bolus systems (4h), though at higher cost. Key selection criteria include purity (>98%), cold-chain logistics (2-8°C), and FDA/EMA certifications. Emerging technologies (e.g., oral bolus delivery) improve patient compliance but face enzymatic degradation challenges. The sector’s future hinges on scalable manufacturing and regulatory harmonization.